Final Patient Treated in Clinical Trials for Active Implants’ NUsurface® Meniscus Implant

July 10, 2018

MEMPHIS, Tenn.–(BUSINESS WIRE)–Active Implants LLC, a company that develops orthopedic implant solutions, today announced that the final patient was treated in the two clinical trials evaluating the NUsurface® Meniscus Implant for the treatment of persistent knee pain caused by injured or deteriorated meniscus tissue. The trials are being conducted to evaluate the safety and effectiveness of the NUsurface Meniscus Implant in support of U.S. Food and Drug Administration (FDA) De Novo 510(k) clearance.

“We are now one step closer to filling the gap in treatment options between minimally invasive meniscus repair and total knee replacement, which is a large unmet need in the orthopedic market,” said Ted Davis, president and CEO of Active Implants. “With enrollment complete, we will continue to work closely with the FDA and now focus our efforts on collecting the data required for the U.S. regulatory submission. We thank our investigator surgeons and patients for making this day possible.”

The two clinical trials enrolled a combined 243 patients, 176 of which received the NUsurface Meniscus Implant. The VENUS (Verification of the Effectiveness of the NUsurface System) trial is a randomized, multi-centered, prospective, controlled study comparing the NUsurface Meniscus Implant to the non-surgical standard of care and enrolled 128 patients at 10 U.S. study sites. The SUN (Safety Using NUsurface) trial is a single-arm study assessing the safety and probable benefit of the NUsurface Meniscus Implant in restoring function similar to that of a natural, healthy meniscus and enrolled 115 patients at 13 U.S. study sites. Active Implants conducted the two different types of studies concurrently in order to bring the NUsurface Meniscus Implant to market as quickly as possible while the company worked with the FDA to finalize the regulatory clearance for marketing in the U.S.

“The NUsurface Implant is being studied in patients who still have persistent knee pain following a meniscus surgery, have exhausted other treatment options, and are too old for repair and too young for total knee replacement,” said Elliott Hershman, MD, orthopedic surgeon at Lenox Hill Hospital in New York City and medical director for the studies.

If approved by the U.S. Food & Drug Administration, the NUsurface Implant would be the first “artificial meniscus.” The meniscus is a tissue pad between the thigh and shin bones, and once damaged, the meniscus in middle aged patients has a very limited ability to heal itself. Current treatment for a damaged or torn meniscus includes pain management, physical therapy, injections, repair techniques or meniscectomy. It has been estimated that from 700,000 to over 1 million partial meniscectomies are performed annually in the U.S. in an attempt to alleviate pain; however, recent studies have shown that many people who get a meniscectomy continue to experience pain that impacts their quality of life and can eventually lead to knee replacement surgery.

About the NUsurface® Meniscus Implant

The NUsurface® Meniscus Implant is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. It is made from medical grade polymer and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissues. The NUsurface Meniscus Implant mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. The NUsurface Meniscus Implant has been used in Europe under CE Mark since 2008 and in Israel since 2011.

About Active Implants LLC

Active Implants LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in Haarlem, The Netherlands, with R&D facilities in Netanya, Israel. For more information, visit

CAUTION Investigational device. Limited by United States law to investigational use.


Merryman Communications
Joni Ramirez, 323-532-0746

Catalyst OrthoScience Adds Brian K. Hutchison to Board of Directors as Executive Chair, Interim CEO

June 28, 2018

NAPLES, Fla.–(BUSINESS WIRE)–Catalyst OrthoScience Inc., a cutting-edge medical device company focused on the upper extremity orthopedics market, today announced the addition of Brian K. Hutchison to its board of directors as executive chair. Hutchison will also serve as interim chief executive officer of the company until a permanent CEO is in place.

Hutchison replaces Robert M. Kaufman, who has served as chairman and CEO of Catalyst OrthoScience since August 2017.

“We are pleased to have Brian join our board and immediately step in as executive chair and interim CEO,” said Steven Goldberg, M.D., founder of Catalyst OrthoScience. “He brings a wealth of experience in orthopedics and executive leadership to our company at a critical stage of growth.”

“I am excited to join the Catalyst board of directors as executive chairman and interim CEO,” Hutchison said. “In the coming months I will be focused on assessing the company’s structure and filling the gaps on the leadership team, including recruiting a permanent CEO. I believe the Catalyst CSR™ Total Shoulder System is one of the best shoulder replacement technologies on the market today, and I look forward to continued sales growth as we expand our market presence.”

Hutchison brings more than 30 years of healthcare industry experience to the Catalyst OrthoScience board. Most recently, Hutchison retired after serving 15 years as CEO of RTI Surgical Inc. (NASDAQ: RTIX). At RTI Surgical, he grew annual revenue from $55 million to $300 million, positioning the company as a leader in advanced biologic products. As CEO, Hutchison successfully merged RTI Surgical with Tutogen Medical in 2008 and in 2013 acquired Pioneer Surgical Technologies. Over his tenure, he secured multiple rounds of financing that included a $25.8 million investment in 2002 and a $22.2 million investment in 2005.

Before RTI Surgical, Hutchison held various positions at Stryker Corporation, including serving as vice president of worldwide product development and distribution, senior vice president and chief operation officer of the Howmedica Osteonics Division and president of the Stryker Medical Division.

Hutchison currently serves on the board of directors of Zavation Medical Products and the University of Florida Research Foundation. He received a bachelor’s degree in accounting from Grand Valley State University and attended Harvard Business School’s Program for Management.

About Catalyst OrthoScience Inc.

Catalyst OrthoScience develops and markets surgical implants that make orthopedic surgery less invasive and more efficient for both surgeons and patients. Catalyst was founded in 2014 by orthopedic surgeon Steven Goldberg, M.D., who saw the need to make shoulder replacement surgery less invasive and give patients a more natural-feeling shoulder after surgery.

The company’s first offering, the Catalyst CSR Total Shoulder System, represents the next evolution in stemless total shoulder arthroplasty. The Catalyst CSR is a single-tray, bone-preserving total shoulder arthroplasty system containing a precision elliptical humeral head and less invasive glenoid component, using specialized ergonomic instrumentation designed for consistent anatomic joint line restoration and glenoid insertion. The Catalyst CSR system can be used in both inpatient and outpatient settings and was cleared for use by the FDA in 2016.

Catalyst OrthoScience has a growing portfolio of 10 granted U.S. patents with several more pending nationally and internationally. The company is headquartered in Naples, Fla., and its products are available across the U.S. For additional information on the company, please visit


Catalyst OrthoScience Inc.
Brian K. Hutchison
Surgence Communications Strategies
Wendy Crites Wacker, APR, 352-494-2129

Exactech’s Truliant® Knee System Honored as Winner in the Medical Design Excellence Awards (MDEA)

June 26, 2018

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced that the new Truliant® Knee System has been selected as the Silver Award Winner in the Implant and Tissue Replacement Products category of the 20th Annual Medical Design Excellence Awards (MDEA) competition. Winners in this leading medtech industry awards program were announced earlier this month in New York.

Exactech’s Truliant Knee System is a comprehensive platform of implants and instrumentation designed to address the remaining clinical challenges of total knee replacement. Leveraging Exactech’s core principles and advanced design philosophies, Truliant is supported by ExactechGPS® guided personalized surgery and is developed to help surgeons deliver reproducible clinical outcomes in a streamlined procedure.

The MDEA award is the Truliant Knee System’s second industry recognition. Last year, Truliant’s surgical instrumentation was honored with an International Design Excellence (IDEA®) Award by the Industrial Designers Society of America. For more information, visit

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at


Priscilla Bennett, 352-377-1140
Vice President of Corporate and Marketing Communications


Exactech’s Truliant(R) Knee System Honored as Winner in the Medical Design Excellence Awards. (Photo: Business Wire)

Bradford S. Waddell, M.D. Becomes First Surgeon In Connecticut to Implement HIPALIGN®, Handheld Sensor-based Navigation for DA Total Hip Surgery

Stamford, CT, June 26, 2018 (GLOBE NEWSWIRE) — Dr. Brad Waddell is the first surgeon in Connecticut to offer HipAlign® for direct-anterior total hip replacement. HipAlign is a sensor-based navigation technology that helps surgeons perform precise and accurate hip replacement surgeries. The HipAlign system allows Dr. Waddell to offer his patients one of the most advanced surgical technologies available in Connecticut.

The HipAlign technology acts as a GPS for surgeons, using micro-electromechanical sensors like accelerometers and gyroscopes to guide hip replacement surgery, to ensure accuracy and alignment. All of this happens in a phone-like device that sits in the surgeon’s hands, and on their surgical instruments.

“Using HipAlign technology allows for accurate placement of the hip prosthesis by using patient’s individual pelvic anatomy,” said Dr. Waddell, Orthopedic Surgeon at Hospital for Special Surgery. “Cost-effective navigation and smart instrumentation like HipAlign is the future of technology in orthopedic surgery. It’s important in that the technology allows me to combine my clinical experience and decision making along with real-time data about my patient. The resulting precision may lead to improved outcomes for my patients.” Dr. Waddell works with OrthAlign in a personal capacity.

The HipAlign technology (manufactured by OrthAlign, Inc. a California-based company) launched in 2018, building on the legacy of KneeAlign®, a technology that has powered more than 75,000 surgeries to date.

To learn more about the HipAlign surgical procedure, visit 


OrthAlign is a privately held medical device and technology company, developing advanced technologies that deliver healthier and more pain-free lifestyles to joint replacement patients, globally. We provide healthcare professionals with cutting edge, computer-assisted surgical tools that seamlessly and cost-effectively deliver vital data and clinical results to optimize outcomes for our patients. For more information regarding OrthAlign, please visit or contact Adam Simone (


Adam Simone

Peer Reviewed Results: Conformis Patient Specific iTotal CR Achieves Better Rotational Alignment and Tibial Fit Compared to Off-the-Shelf Implants

BILLERICA, Mass., June 25, 2018 (GLOBE NEWSWIRE) — Conformis Inc. (NASDAQ:CFMS), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell patient specific joint replacement implants designed to fit each patient’s unique anatomy, today announced publication of a study showing that patients treated with the iTotal CR Knee Replacement Systems achieved better tibial fit and tibial rotational alignment compared to patients treated with three different off-the-shelf (OTS) total knee arthroscopy (TKA) products. Results of the study titled “In Vivo Tibial Fit and Rotational Analysis of a Customized, Patient-Specific TKA versus Off-the-Shelf TKA” were presented in the May 2018 issue of The Journal of Knee Surgery, a leading peer-reviewed orthopedic journal.

The study, which was conducted jointly by Greg Martin, MD in Boynton Beach, Florida and Lennart Schroeder, MD candidate Julius-Maximilians-Universitaet Wuerzburg, Germany, intraoperatively compared component fit in four tibial zones. The Conformis iTotal CR implant system and three OTS cruciate retaining TKA products including Biomet Vanguard, Zimmer NexGen and DePuy Sigma were evaluated intraoperatively in a total of 44 knees. Each implant system was evaluated intraoperatively on the same 44 knees to compare each brand’s optimal tibial fit. Component rotation was then evaluated post operation using CT-based imaging converted into computer aided design (CAD) models. Using these models, simulated surgery was performed with the OTS TKAs.

“One of the compromises and decisions we surgeons often need to make intraoperatively is the best method to achieve an optimal “fit” for the patient while maintaining proper rotational alignment,” says board certified, fellowship trained hip and knee surgeon, Gregory Martin, MD. “The real benefit that I’ve found using Conformis implants is that this compromise is completely obviated. The implants fit precisely as designed with the in-built rotation, and enough relief to allow me to fine tune my rotation based on the specific patient’s anatomy. This is borne out in our results.”

The surgeon placed all implants with proper rotational alignment and the results of this study show: 37% of OTS knees showed >3mm under-coverage compared to 18% of Conformis iTotal and 18% of OTS had an overhang of >3mm compared to 0% for iTotal. In previous studies1, component overhang of greater than 3mm was linked to significantly higher post-operative pain. Additionally, when the same 44 knees were positioned for optimal fit, 45% of OTS knees had rotational errors of >5 degrees and 4% had >10 degrees. Excessive internal tibial component rotation has been found to be one of the leading factors of residual pain in TKR and can be a source of functional deficit2. No rotational deviation was observed with the Conformis iTotal implants, which are pre-aligned rotationally to match the patient’s unique anatomy.

“This is the first study to evaluate both the fit of the tibial tray and rotation of our patient-specific designed implants compared with off-the-shelf implants,” said Mark Augusti, chief executive officer and president of Conformis. “We often hear from surgeons that when they use off-the-shelf implants they need to compromise either on fit or rotation in the operating room. The results of this new study demonstrate that the Conformis iTotal CR can help surgeons address both issues at the same time. This study adds to the growing body of evidence that the Conformis iTotal CR can lead to better outcomes for patients.”




Semi-Automated Design Program Could Develop Patient-Specific Knee Implants

Stellenbosch University – 06.19.18

People whose knees have been affected by osteoarthritis, also known as the “wear and tear” arthritis, often have to get knee implants to repair the damage. But if a knee implant does not fit the specific individual, it could lead to soft tissue damage, collapsing of the underlying bone, loosening of the implant and an increased likelihood of joint pain after an operation.

“One possible solution is to design implants that are patient-specific, anatomically accurate, reproduce normal knee motion and are ultimately repeatable,” said Dr. Johan van der Merwe, a lecturer in the Department of Mechanical and Mechatronic Engineering at Stellenbosch University (SU). Van der Merwe, who is also a member of the Biomedical Engineering Research Group in the same department, recently obtained his doctorate in Mechatronic Engineering at SU. He focused on developing a repeatable, semi-automated method of generating patient-specific implant components that reproduces an individual’s healthy anatomy to facilitate natural joint movement after an operation.

Van der Merwe pointed out that the knee is one of the joints most susceptible to osteoarthritis, a form of arthritis that occurs when the protective cartilage in joints breaks down.

Van der Merwe said for localized osteoarthritis, surgical reconstruction or replacement of only the damaged part of the knee (Unicompartmental Knee Arthroplasty) may be preferred over the replacement of the entire joint (Total Knee Arthroplasty). Projections are that by 2030 three million knee replacement surgeries will be done globally. Current knee replacements usually last for 10 years.

“Replacing or repairing only the damaged part may result in faster recovery, improved post-operative joint movement, retains as much of the joint’s natural anatomy as possible and is done at a lower cost,” he said. “But designing patient-specific Unicompartmental Knee Replacements ultimately rely on a technician’s interpretation and skill in order to consistently reproduce healthy knee shapes. This is a difficult problem—what is considered healthy for one patient might not be the same for another.”

Van der Merwe pointed out that there is often a mismatch between current standardized sizes of commercially available implants and the shape and form of an individual patient’s knee. This generally requires the surgeon to make the patient fit the implant, and sometimes even deviate from the ideal intended implant placement based on experience and current best practices to achieve good outcomes.

In an attempt to address these shortcomings, Van der Merwe developed a model based on the various shapes of healthy knees, which could then be used to estimate the healthy shape of damaged parts on a patient’s knee.




Image courtesy of Dr. Johan van der Merwe


Exactech Earns Research Award at International Computer-Assisted Surgery Conference for ExactechGPS® Knee Application

June 20, 2018

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, a leading developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, earned the Second Place Best Clinical Podium Presentation Award for one of five new research studies presented on the company’s latest computer guidance technology for knee surgery at the International Society for Computer Assisted Orthopaedic Surgery (CAOS) annual meeting in Beijing, China earlier this month.

The award-winning research demonstrated the potential for ExactechGPS to accurately manage soft tissue balance, bone cuts and overall alignment of the knee in joint replacement surgery.

According to Orthopaedic Surgeon David Liu, MD, of The Gold Coast Centre for Bone & Joint Surgery in Queensland, Australia, “It was an honour to present several studies based on ExactechGPS and to receive this award, along with my co-authors Yifei Dai and Guillaume Bras of Exactech. This scientific meeting is unique in its focus on the role of navigation in orthopaedic surgery. I am confident that this technology plays a major role in the outcomes of joint arthroplasty.”

The five ExactechGPS studies presented at CAOS 2018 add to the more than 20 presented so far this year, including one that was recognized as the 2018 Orthopaedic Research Society’s Best Implant Poster Award. For more information on Exactech’s solutions for knee replacement and its ExactechGPS technology, visit

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at


Media Contact:
Priscilla Bennett, 352-377-1140
VP of Marketing and Corporate Communications, Exactech

Positive Knee Preservation Outcomes Using the Innovative Arthrosurface Inlay PF Wave™

FRANKLIN, Mass.June 19, 2018 /PRNewswire/ — Arthrosurface, Inc. announced today that midterm clinical results reconfirmed joint preservation in patellofemoral (PF) surgery with the PF Wave™ Implant System. 5-year results presented by Dr. Jonas Pogorzelski at the recent ESSKA Congress in Glasgow, Scotland found significant improvement in symptoms and no progression of knee arthritis.

Isolated patellofemoral arthritis occurs when there is loss of cartilage limited to the central portion of the knee joint. For advanced stages, partial joint replacement has become the leading treatment. The Arthrosurface PF Wave Inlay Arthroplasty Design adapts and restores the patient’s unique joint surface providing a novel, anatomic approach to treating isolated patellofemoral arthritis. Derek Jones, MD, Section head of Sports Medicine and Cartilage Restoration at the Ochsner Sports Medicine Institute in New Orleans said, “Over the course of the past 8 years, I have been very encouraged seeing my patients return to high levels of work and sports following this procedure. Our joint preservation experience is similar to those presented at ESSKA.” In contrast, traditional Onlay implants require more extensive bone cuts and tend to sit high on the new joint surface, thereby increasing the risk of overstuffing the joint.

Based on their findings presented at ESSKA, lead author Prof. Andreas Imhoff, Professor of Orthopaedic Surgery and Traumatology, Director/Chairman Department of Orthopaedic Sports Medicine at the University of Munich concluded, “We observed significantly improved postoperative outcomes with high patient satisfaction at the two-year follow up. This trend held true for the 5-year results, too.”

According to Matthias Schurhoff, VP of Clinical Affairs, “seeing these study results continue to show no arthritic changes at the 5-year mark while holding significant pain relief and functional improvement is very validating for us. These results support our belief that our unique inlay concept provides a contemporary arthroplasty track in patellofemoral surgery.”

Arthrosurface continues to innovate Patellofemoral Arthroplasty by providing active alternatives to total knee replacement and allowing more patients access to knee preservation options.

About Arthrosurface: Arthrosurface, Inc. is a global orthopedic medical technology business providing a broad portfolio of essential products and instrumentation used to treat upper and lower extremity orthopedic conditions caused by trauma, injury and arthritic disease. Arthrosurface is the inventor and market leader in joint preservation with inlay arthroplasty. Our product offerings include joint preservation implants, instruments and orthobiologics. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world and has succeeded in helping patients return to activity for over 14 years. For more information, please visit our website at

SOURCE Arthrosurface, Inc.

Related Links

Medacta Launches Short Humeral Diaphysis for the Medacta Shoulder System at the San Diego Shoulder Institute’s Annual Shoulder Course

June 18, 2018

SAN DIEGO–(BUSINESS WIRE)–Medacta® International, the privately held family-owned global leader in the design of innovative joint replacement and spine surgery products, today announced clearance by the U.S. Food and Drug Administration (FDA) for its Short Humeral Diaphysis, which is utilized with the Medacta Shoulder System. The company will showcase this new product at the San Diego Shoulder Institute’s (SDSI) Annual Shoulder Course, held June 20-23 in San Diego at Booth #310. Medacta will host numerous “Meet the Expert” opportunities with orthopedic surgeon designers Matthew Saltzman, M.D., and Anup Shah, M.D., throughout the conference and lead cadaveric workshops on Thursday, June 21 as a part of its M.O.R.E. Institute.

The Short Humeral Diaphysis is an implantable device that replaces the humeral side of the gleno-humeral joint and is intended for use with the Medacta Shoulder System as an alternative to the Standard Humeral Diaphysis. The Short Humeral Diaphysis is indicated for primary and reverse shoulder replacement in patients suffering from severe arthropathy or a grossly deficient rotator cuff. Through a reduction in device length, the corresponding procedure minimizes the violation of the humeral intramedullary canal (IM). The device is manufactured from titanium alloy and will be offered in 11 sizes to provide a patient-matched fit.

“Medacta is constantly looking to expand its product offerings to accommodate the largest group of unique patient anatomies as possible,” said Francesco Siccardi, Executive Vice President of Medacta International. “We’ve experienced a very positive response to our recent expansion into the shoulder market and are looking to build on that success. The addition of the Short Humeral Diaphysis to the Medacta Shoulder System means that surgeons will be able to achieve a more personalized fit for more patients, improving the patient and surgeon experience.”

Medacta Activities at SDSI’s 35th Annual Shoulder Course

Medacta will showcase this new product at Booth #310 along with the full Medacta Shoulder System and will offer various opportunities for conference attendees to experience its products and meet with members of the team. The full schedule of Medacta’s on-site offerings is listed below.

Thursday, June 21: Medacta Shoulder System Cadaveric Workshops

  • 6:30 a.m. – 7:00 p.m.

Wednesday, June 20-Friday, June 22: “Meet the Experts” Sessions with Drs. Saltzman and Shah

  • 7:00 a.m. – 5:00 p.m. each day

Conference attendees interested in scheduling “Meet the Expert” appointments or attending Medacta’s wet lab sessions should contact Amanda Earl ( Additional workshops may be added to the schedule to accommodate requests, as needed.

About the M.O.R.E. Institute – “Where the surgeon is never alone”

Strongly aware of its role to provide continuing education as products and techniques evolve, Medacta International founded the M.O.R.E. (Medacta Orthopaedic Research and Education) Institute to highlight this commitment. Built on the ideal of sharing experience within the international medical community, the mission of the M.O.R.E. Institute is to provide ongoing support to Medacta partners worldwide as they strive to make an impact by learning about and adopting emerging technologies, surgical techniques and orthopaedic products. The Institute includes the AMIS Education Program for total hip arthroplasty, which has revolutionized the teaching of the anterior approach to hip replacement throughout the world, as well as platforms to impact the specialties of partial and total knee arthroplasty, total and reverse shoulder arthroplasty, sports medicine and spine surgery. The Institute relies on Medacta consultants and the healthcare provider community to create networking opportunities and hundreds of educational events, including courses, wet labs, scientific evenings, surgeon-to-surgeon visits, international symposia, guesting and hosting thousands of participants from all over the world. With a strong focus on young and promising surgeons, the M.O.R.E. Institute also supports fellowship programs worldwide.

About Medacta International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient-matched technology. Over the last 10 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit or follow @Medacta on Twitter and LinkedIn.


For Medacta International, Inc.
Emy Gruppo, 203-247-5856

OrthoGrid Systems Announces Immediate Launch of New HipGrid® NINE for Outpatient Total Hip Replacement

SALT LAKE CITYJune 18, 2018 /PRNewswire/ — OrthoGrid Systems, Inc., a leading innovator of radiographic assessment and alignment technology for orthopedics, today announced the commercial release of its new patent-protected HipGrid® NINE System for outpatient total hip replacement.  Featuring the same clinically validated technology utilized in the original HipGrid®, OrthoGrid’s HipGrid® NINE system is designed to seamlessly integrate with C-arm systems commonly found at ambulatory surgical centers and hospitals.

“Outpatient total hip replacement procedures are growing rapidly due in large part to the potential for added convenience, reduced costs, and quicker return to home for the patient,” explained Edouard Saget, President of OrthoGrid Systems.  “Increasingly, our customers have demanded to have a HipGrid® that is compatible with 9-Inch C-arm systems commonly found in outpatient surgery centers, and so we are pleased to immediately commence shipments of this compelling new product.”

Designed with an innovative BOA® Fit Attachment System and high contrast markings, the HipGrid® NINE is controlled intra-operatively by the physician, integrates into the standard surgical workflow with no disposables or instrumentation, and can be fully utilized in conjunction with implant systems from all vendors.

Orthopedic surgeon Erik Kubiak, MD, noted that, “as the healthcare system moves away from unconstrained spending and physicians and hospitals work together to deliver higher-quality care for a reasonable cost, OrthoGrid’s HipGrid® NINE hits the mark by enabling excellent clinical value at an attractive economic price.  I will continue relying on OrthoGrid technologies for my total hip replacement patients.”

The HipGrid® NINE System is available for sale in the USA through OrthoGrid’s sales & service team.  Please visit our website at to learn more about our company and how to schedule a free product trial of any OrthoGrid Systems technology.

About OrthoGrid Systems, Inc.
OrthoGrid Systems is a rapidly expanding global leader in intra-operative radiographic assessment and alignment technologies for orthopedics, with specialized applications available or in development for hip arthroplasty, trauma, knee replacement, and other common procedures performed over 1 million times per year in aggregate in the USA and 3 million times globally.  OrthoGrid helps to overcome the limitations of traditional low resolution, distorted imaging technology by revealing inherent image distortion, enhancing intra-operative decision making for physicians performing orthopedic procedures.  Learn more about OrthoGrid and our products by visiting our website at

Media Contact: Mark Carrico. Director of Marketing
Phone: 801-703-5866

SOURCE OrthoGrid Systems

Related Links